Primary Progressive Multiple Sclerosis

M. Filippi

ISBN 10: 8847022363 / ISBN 13: 9788847022362

Published by Springer, Springer Mär 2012, 2012

About this Item

This item is printed on demand - Print on Demand Titel. Neuware -'Why are there no effective treatments for my condition Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. ' Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 140 pp. Englisch.

Seller Inventory # 9788847022362

Bibliographic Details

• Title: Primary Progressive Multiple Sclerosis
• Publisher: Springer, Springer Mär 2012
• Publication Date: 2012
• Language: English
• ISBN 10: 8847022363
• ISBN 13: 9788847022362
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 235W x 155H x 8D millimeters 235 millimeters width by 155 millimeters height by 8 millimeters depth
• Weight: 224 grams

About this title

Synopsis

"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin­ ical trials have excluded PPMS patients on two counts. Clinical worsening devel­ ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi­ ence suggests that the results may not be dramatic.